Shenzhen Hepalink Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio
Shenzhen Hepalink Pharmaceutical Co Ltd cash flow-to-debt ratio. Shenzhen Hepalink Pharmaceutical Co Ltd (002399) has a Cash Flow-to-Debt Ratio of 0.08x as of September 2025, meaning its operating cash flow of CN¥399.43 Million could theoretically repay 0% of its total liabilities (CN¥4.70 Billion) in one year. Check Shenzhen Hepalink Pharmaceutical Co Ltd (002399) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Shenzhen Hepalink Pharmaceutical Co Ltd (2006–2025)
Cash flow-to-debt ratio of Shenzhen Hepalink Pharmaceutical Co Ltd from 2006 to 2025. Historical debt coverage capacity for Shenzhen Hepalink Pharmaceutical Co Ltd across 20 annual periods. Check how aggressively does Shenzhen Hepalink Pharmaceutical Co Ltd reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Shenzhen Hepalink Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio by Year (2006–2025)
Shenzhen Hepalink Pharmaceutical Co Ltd cash flow-to-debt ratio by year from 2006 to 2025. Year-by-year debt coverage analysis for Shenzhen Hepalink Pharmaceutical Co Ltd. For the full cash flow conversion analysis, see Shenzhen Hepalink Pharmaceutical Co Ltd (002399) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.38x | CN¥1.71 Billion | CN¥4.55 Billion | ▼ -11.8% |
| 2024 | 0.43x | CN¥2.19 Billion | CN¥5.14 Billion | ▲ +673.2% |
| 2023 | 0.06x | CN¥398.22 Million | CN¥7.22 Billion | ▲ +161.3% |
| 2022 | -0.09x | CN¥-756.61 Million | CN¥8.41 Billion | ▼ -10197.5% |
| 2021 | 0.00x | CN¥-6.63 Million | CN¥7.58 Billion | ▼ -117.2% |
| 2020 | 0.01x | CN¥37.28 Million | CN¥7.34 Billion | ▲ +117.4% |
| 2019 | -0.03x | CN¥-227.60 Million | CN¥7.77 Billion | ▼ -132.5% |
| 2018 | 0.09x | CN¥667.87 Million | CN¥7.41 Billion | ▲ +221.8% |
| 2017 | -0.07x | CN¥-407.12 Million | CN¥5.50 Billion | ▼ -203.2% |
| 2016 | 0.07x | CN¥346.07 Million | CN¥4.83 Billion | ▼ -72.9% |
| 2015 | 0.26x | CN¥893.71 Million | CN¥3.38 Billion | ▼ -54.2% |
| 2014 | 0.58x | CN¥912.80 Million | CN¥1.58 Billion | ▼ -72.0% |
| 2013 | 2.07x | CN¥420.97 Million | CN¥203.80 Million | ▼ -6.5% |
| 2012 | 2.21x | CN¥473.89 Million | CN¥214.53 Million | ▼ -90.6% |
| 2011 | 23.43x | CN¥1.41 Billion | CN¥59.98 Million | ▲ +582.9% |
| 2010 | 3.43x | CN¥354.86 Million | CN¥103.44 Million | ▲ +195.4% |
| 2009 | 1.16x | CN¥355.81 Million | CN¥306.33 Million | ▲ +684.7% |
| 2008 | 0.15x | CN¥40.13 Million | CN¥271.09 Million | ▲ +19.0% |
| 2007 | 0.12x | CN¥13.85 Million | CN¥111.28 Million | ▼ -55.3% |
| 2006 | 0.28x | CN¥71.66 Million | CN¥257.68 Million | — |